Reston – January 3, 2017 – Cooley advised Clearside Biomedical on its $36 million public offering of 4,000,000 shares of common stock.
Clearside, which trades on the NASDAQ Global Market under the symbol “CLSD,” is a late-stage clinical biopharmaceutical company developing innovative drug therapies to treat blinding diseases of the eye.
In addition to representing Clearside on the offering, Cooley has served as intellectual property counsel to the company since 2012. Earlier this year, Cooley also advised
Clearside on its $50 million IPO.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.